Osteoarthritis: An Update on Data Currently Reshaping Practice

Abstract

Osteoarthritis is common, has considerable health consequences, and will affect increasing numbers of persons in coming years. Nonpharmacological interventions are of paramount importance in achieving adequate symptom control. Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) play a pivotal role in osteoarthritis pharmacotherapy. Acetaminophen, due to its safety profile, should be adequately trialed before resorting to NSAIDs. NSAIDs and celecoxib, a selective inhibitor of cyclooxygenase-2, should be selected thoughtfully so as to balance the likelihood of treatment success with gastrointestinal bleeding and cardiovascular events. Celecoxib may be used when the risk for gastrointestinal bleeding is high and the risk of cardiovascular events low. Otherwise, NSAIDs, usually naproxen, should be paired with a gastroprotective agent. Topical NSAIDs, including a recently approved diclofenac patch and gel, may also be useful when systemic exposure is undesirable. The role of glucosamine and chondroitin is controversial and the data conflicting. Other modalities, such as tramadol, opioids, and viscosupplementation should be tailored to the patient and clinical situation. Appropriate deployment of agents in the osteoarthritis armamentarium can maximize efficacy and safety thereby improving the disease burden for patients.

Keywords

arthritis osteoarthritis nonsteroidal anti-inflammatory drugs acetaminophen cyclooxygenase 2 inhibitors

Get full access to this article

View all access options for this article.

References

Epstein BJ , Gums JG , Hall K. ``OA'' in Pharmacotherapy Principles and Practice. Chisholm-Burns MA , Wells BG , Schwinghammer TL , et al., eds. New York, NY: McGraw-Hill; 2007: Chapter 55.

Lane NE Osteoarthritis of the hip. N Engl J Med. 2007 ;357:1413-1421.

Dieppe PA , Lohmander LS Pathogenesis and management of pain in OA. Lancet . 2005;365:965-973.

Sahlstrom A. , Johnell O. , Redlund-Johnell I. The natural course of arthrosis of the knee. Clin Orthop. 1997;340: 152-157.

Dieppe PA , Cushnaghan J. , Shepstone L. The Bristol `OA500' study: progression of osteoarthritis (OA) over 3 years and the relationship between clinical and radiographic changes at the knee joint. Osteoarthr Cartil. 1997;5:87-97.

Dieppe P. , Cushnaghan J. , Tucker M. , et al. The Bristol `OA500 study': progression and impact of the disease after 8 years. Osteoarthr Cartil. 2000;8:63-68.

Paradowski PT , Englund M. , Roos EM , Lohmander LS Similar group mean scores, but large individual variations, in patient relevant outcomes over 2 years in meniscectomized subjects with and without radiographic knee OA. Health Qual Life Outcomes . 2004;2:38.

Scanzello CR , Moskowitz NK , Gibofsky A. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in OA. Curr Pain Headache Rep. 2007;11:415-422.

Khanna D. , Khanna PP , Furst DE COX-2 controversy: where are we and where do we go from here? Inflammopharmacology. 2005;13:395-402.

10.

Bruyere O. , Reginster JY Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging. 2007;24:573-580.

11.

Avouac J. , Gossec L. , Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2007 ;15:957-965.

12.

Altman RD Criteria for classification for clinical OA. J Rheumatol. 1991;18(suppl):10-12.

13.

Altman R. , Alarcon G. , Appelrouth D. , et al. The American College of Rheumatology criteria for classification and reporting of OA of the hand. Arthritis Rheum. 1990;33: 1601-1610.

14.

Osborne RH , Wilson T. , Lorig KR , McColl GJ Does self-management lead to sustainable health benefits in people with arthritis? A 2-year transition study of 452 Australians. J Rheumatol . 2007;34:1112-1117.

15.

Warsi A. , LaValley MP , Wang PS , Avorn J. , Solomon DH Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum. 2003 ;48:2207-2213.

16.

Weinberger M. , Tierney WM , Cowper PA , Katz BP , Booher PA Cost-effectiveness of increased telephone contact for patients with OA. A randomized, controlled trial. Arthritis Rheum. 1993;36:243-246.

17.

Van Baar ME , Assendelft WJJ , Dekker J. , Oostendorp RAB , Bijlsma JW Effectiveness of exercise therapy in patients with OA of the hip or knee: a systematic review of randomized clinical trials . Arthritis Rheum. 1999;42:1361-1369.

18.

Messier SP , Loeser RF , Miller GD , et al. Exercise and dietary weight loss in overweight and obese older adults with knee OA: the Arthritis, Diet and Activity Promotion Trial. Arthritis Rheum. 2004;50:1501-1510.

19.

Witt Cm , Jena S. , Brinkhaus B. , Liecker B. , Wegscheider K. , Willich SN Acupuncture in patients with OA of the knee or hip: a randomized, controlled trial with an additional nonrandomized arm . Arthritis Rheum. 2006;54:3485-3493.

20.

Berman BM , Lao L. , Langenberg P. , Lee WL , Gilpin AM , Hochberg MC Effectiveness of acupuncture as adjunctive therapy in OA of the knee: a randomized controlled trial. Ann Intern Med. 2004;141:901-910.

21.

Altman RD , Zinsenheim JR , Tample AR , Schweinle JE Three-month efficacy and safety of acetaminophen extended release for OA pain of the hip or knee: a randomized, double-blind,placebo-controlled trial. Osteoarthr Cartil. 2007;15:454-461.

22.

Amadio P. , Cummings DM Evaluation of acetaminophen in the management of OA of the knee. Curr Ther Res. 1983;34:59-66.

23.

Bradley JD , Brandt KD , Katz BP , Kalasinski LA , Ryan SL Comparison of an inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with OA of the knee. N Engl J Med. 1991;325:87-91.

24.

Williams JH , Ward JR , Egger JM , Neuner R. , et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of OA of the knee . Arthritis Rheum. 1993;36:1196-1206.

25.

American College of Rheumatology Subcommittee on OA Guidelines. Recommendations for the medical management of OA of the hip and knee: 2000 Update. Arthritis Rheum. 2000;43:1905-1915.

26.

American Pain Society. Guideline for the management of pain in OA, rheumatoid arthritis, and juvenile chronic arthritis. Am Pain Soc. 2002;2:43-74.

27.

Watkins PB , Kaplowitz N. , Slattery JT , et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA . 2006;296:87-93.

28.

Williams GW An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Curr Pain Headache Rep. 2005;9:377-389.

29.

Zhang W. , Doherty M. , Arden N. , et al. EULAR evidence based recommendations for the management of hip OA: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64: 669-681.

30.

Case JP , Baliunas AJ , Block JA Lack of efficacy of acetaminophen in treating symptomatic knee OA: a randomized, double-blind,placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med. 2003;163: 169-178.

31.

Towheed TE , Maxwell L. , Judd MG , Catton M. , Hochberg MC , Wells G. Acetaminophen for OA. Cochrane Database Syst Rev. 2006;1:CD004257.

32.

Altman RD and IAP Study Group. Ibuprofen, acetaminophen and placebo in OA of the knee: a six-day double-blind study [abstract]. Arthritis Rheum. 1999;42(suppl 9):S403.

33.

Moore RA , Derry S. , Phillips CJ , McQuay HJ Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7:79.

34.

Kearney PM , Baigent C. , Godwin J. , Halls H. , Emberson JR , Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials . BMJ. 2006;332:1302-1308.

35.

ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1:E33. doi:10.1371/ journal.pctr.0010033.

36.

Strand V. Are COX-2 inhibitors preferable to nonselective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin ? Lancet. 2007;370:2138-2151.

37.

Hersh EV , Pinto A. , Moore PA Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29(suppl):2477-2497.

38.

Catella-Lawson F. , Reilly MP , Kapoor SC , et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.

39.

Gaziano JM , Gibson CM Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol . 2006;97:23-29.

40.

Meune C. , Mourad JJ , Bergmann JF , Spaulding C. Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance. J Renin Angiotensin Aldosterone Syst. 2003;4: 149-154.

41.

Laine L. , White WB , Rostom A. , Hochberg M. COX-2 Selective Inhibitors in the Treatment of OA. Semin Arthritis Rheum. 2008 January 3 [Epub ahead of print].

42.

McGettigan P. , Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006 ;296:1633-1644.

43.

Kimmel SE , Berlin JA , Reilly M. , et al. Patients exposed to rofecoxib and celecoxib have different odds of non-fatal myocardial infarction. Ann Intern Med. 2005;142: 157-164.

44.

Mukherjee D. , Nissen SE , Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.

45.

Funk CD , Fitzgerald GA COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol . 2007;50:470-479.

46.

Zullo A. , Hassan C. , Campo SM , Morini S. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies . Drugs Aging. 2007;24:815-828.

47.

Bombardier C. , Laine L. , Reicin A. , et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1508.

48.

Laine L. , Curtis SP , Cryer B. , et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with OA and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) program: a randomized comparison. Lancet. 2007;369:465-473.

49.

SchnitzerTJ , Burmester GR , Mysler E. , etal. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial . Lancet. 2004;364: 665-674.

50.

Bertagnolli MM , Eagle CJ , Zauber AG , et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med . 2006;355:873-884.

51.

Arber N. , Eagle CJ , Spicak J. , et al. Celecoxib for the prevention of colorectal adenomatous polyps . N Engl J Med. 2006;355:885-895.

52.

Solomon SD , Pfeffer MA , McMurray JJ , et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-1035.

53.

Farkouh ME , Kirshner H. , Harrington RA , et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet . 2004;364:675-684.

54.

Scheiman JM , Fendrick AM Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Res Ther. 2005;7(suppl 4):S23-S29.

55.

Rozendaal RM , Koes BW , van Osch GJ , et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med . 2008;148:268-277.

56.

Richy F. , Bruyere O. , Ethgen O. , et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee OA: a comprehensive meta-analysis. Arch Intern Med . 2003;163:1514-1522.

57.

Towheed TE , Maxwell L. , Anastassiades TP , et al. Glucosamine therapy for treating OA. Cochrane Database Syst Rev. 2005;2:CD002946.

58.

Clegg DO , Reda DJ , Harris CL , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee OA. N Engl J Med. 2006;354:795-808.

59.

Bruyere O. , Reginster JY Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip OA. Drugs Aging. 2007;24:573-580.

60.

Houpt JB , McMillan R. , Wein C. , Paget-Dellio SD Effect of glucosamine hydrochloride in the treatment of pain of OA of the knee. J Rheumatol. 1999;26:2423-2430.

61.

Jackson CG , Plaas AH , Barnhill JG , Harris CL , Clegg DO The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans [abstract]. Arthritis Rheum. 2005;52:4062-4063.

62.

Stumpf JL , Lin SW Effect of glucosamine on glucose control. Ann Pharmacother . 2006;40:694-698.

63.

The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Glen-view, Ill: American Academy of Pain Medicine and American Pain Society, 1997 . Accessed January 23, 2008. Available at: www.ampainsoc.org/advocacy/opioids.htm .

64.

Ballantyne JC , Mao J. Opioid therapy for chronic pain . N Engl J Med. 2003;349:1943-1953.

65.

Hale M. , Tudor IC , Khanna S. , Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe OA pain: results of a 6-week, randomized, open-label, noninferiority analysis . Clin Ther. 2007;29:874-888.

66.

Portenoy RK , Farrar JT , Backonja MM , et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23: 287-299.

67.

Markenson JA , Croft J. , Zhang PG , Richards P. Treatment of persistent pain associated with OA with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005;21:524-535.

68.

69.

Cepeda MS , Camargo F. , Zea C. , Valencia L. Tramadol for OA: a systematic review and meta-analysis. J Rheumatol. 2007;34:543-555.

70.

Cepeda MS , Camargo F. , Zea C. , Valencia L. Tramadol for OA. Cochrane Database Syst Rev. 2006;3:CD005522.

71.

Mason L. , Moore RA , Edwards JE , et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004;328:995-998.

72.

Zhang W. , Doherty M. , Leeb BF , et al. EULAR evidence based recommendations for the management of hand OA: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66: 377-388.

73.

Lin J. , Zhang W. , Jones A. , Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of OA: meta-analysis of randomized controlled trials. BMJ . 2004;329:324.

74.

Underwood M. , Ashby D. , Cross P. , et al, and TOIB study team. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study . BMJ. 2008;336:138-142.

75.

Zhang WY , Li Wan PA The effectiveness of topically applied capsaicin. A meta-analysis . Eur J Clin Pharmacol. 1994;46:517-522.

76.

Lin J. , Zhang W. , Jones A. , Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of OA: meta-analysis of randomised controlled trials. BMJ . 2004;329:324.

77.

Moore RA , Tramer MR , Carroll D. , Wiffen PJ , McQuay HJ Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ. 1998;316:333-338.

78.

Galer BS , Rowbotham M. , Perander J. , Devers A. , Friedman E. Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage. 2000;19:287-294.

79.

Bruhlmann P. , Michel BA Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial . Clin Exp Rheumatol. 2003;21:193-198.

80.

Divine JG , Zazulak BT , Hewett TE Viscosupplementation for knee OA: a systematic review. Clin Orthop Relat Res. 2007;455:113-122.

81.

Bellamy N. , Campbell J. , Robinson V. , Gee T. , Bourne R. , Wells G. Viscosupplementation for the treatment of OA of the knee. Cochrane Database Syst Rev. 2006;2:CD005321.

82.

Strand V. , Conaghan PG , Lohmander LS , et al. An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in OA of the knee. Osteoarthr Cartil. 2006;14:859-866.